Management of type 2 diabetes: the GLP‐1 pathway

Type 2 diabetes mellitus (T2DM) is a major challenge to healthcare systems around the world, with an estimated prevalence of 6% (246 million) in 2007 rising to 7.3% (380 million) in 2025 worldwide.1–5 In this article, the authors consider the significance of the GLP‐1 path‐way in the management of T2DM, and some of the advantages of incretin‐based therapy. Copyright © 2008 John Wiley & Sons, Ltd.